Published in Clin Exp Metastasis on January 01, 1999
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis (2003) 2.56
Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin Exp Metastasis (2004) 1.12
Optically imageable metastatic model of human breast cancer. Clin Exp Metastasis (2002) 1.11
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
Preliminary characterization of an experimental breast cancer cells brain metastasis mouse model by MRI/MRS. MAGMA (2008) 0.86
Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p. Clin Exp Metastasis (2000) 0.80
Improved visualization of lung metastases at single cell resolution in mice by combined in-situ perfusion of lung tissue and X-Gal staining of lacZ-tagged tumor cells. J Vis Exp (2012) 0.78
Detection and quantitation of circulating tumor cell dynamics by bioluminescence imaging in an orthotopic mammary carcinoma model. PLoS One (2014) 0.77
Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer. Curr Biol (1996) 9.72
Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res (1990) 5.41
Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science (1994) 5.37
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro (1978) 4.67
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res (1990) 3.92
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res (1994) 2.20
Energy transfer in a bioluminescent system. J Cell Physiol (1971) 2.13
Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res (1997) 2.00
Metastasis from human breast cancer cell lines. Breast Cancer Res Treat (1996) 1.65
Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. Cancer Res (1998) 1.55
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Cell motility of tumor cells visualized in living intact primary tumors using green fluorescent protein. Cancer Res (1998) 1.49
Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res (1996) 1.35
How cancer spreads. Sci Am (1996) 1.31
Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis (1998) 1.29
The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis (1997) 1.19
Visualization of the metastatic process by green fluorescent protein expression. Anticancer Res (1997) 1.18
An improved green fluorescent protein gene as a vital marker in plants. Plant Physiol (1996) 1.16
Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Res Treat (1998) 1.14
Metastatic patterns of lung cancer visualized live and in process by green fluorescence protein expression. Clin Exp Metastasis (1997) 1.10
The use of a genotypic marker to demonstrate clonal dominance during the growth and metastasis of a human breast carcinoma in nude mice. Int J Cancer (1990) 1.07
Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev (1990) 1.06
Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression. Cancer Res (1990) 1.06
The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis (1997) 1.04
Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy. Int J Cancer (1991) 1.03
Novel gliosarcoma cell line expressing green fluorescent protein: A model for quantitative assessment of angiogenesis. Microvasc Res (1998) 1.03
Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther (1995) 0.98
Luciferase activity as a marker of tumor burden and as an indicator of tumor response to antineoplastic therapy in vivo. Clin Exp Metastasis (1994) 0.96
A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res (1998) 0.95
Detection of brain tumor invasion and micrometastasis in vivo by expression of enhanced green fluorescent protein. Neurosurgery (1998) 0.92
The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. Cancer Metastasis Rev (1995) 0.89
Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci U S A (1996) 0.89
Clonal dominance detected in metastases but not primary tumors of retrovirally marked human breast carcinoma injected into nude mice. Clin Exp Metastasis (1994) 0.85
Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction. Clin Exp Metastasis (1997) 0.84
The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res (1998) 0.81
A model for osseous metastasis of human breast cancer established by intrafemur injection of the MDA-MB-435 cells in nude mice. Anticancer Res (1997) 0.81
Analyzing the metastatic phenotype. J Cell Biochem (1994) 0.79
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 4.18
Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol (1993) 3.00
A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest (1997) 2.37
Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol (1995) 1.55
Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med (2000) 1.44
Deferoxamine in the treatment of acute iron poisoning. Clinical experiences with 172 children. Clin Pediatr (Phila) (1966) 1.40
Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol (1995) 1.37
Leukocyte adhesion to vascular endothelium induces E-selectin linkage to the actin cytoskeleton. J Cell Biol (1996) 1.35
The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer (2003) 1.29
Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A (1994) 1.23
Endothelial modulation of vascular relaxation to nitrovasodilators in aging and hypertension. J Pharmacol Exp Ther (1986) 1.14
Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology (1996) 1.08
Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation. J Clin Invest (1990) 1.07
Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. Circ Res (1999) 1.07
The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] beta-subunit. Endocrinology (1990) 1.05
Site specificity of the chorionic gonadotropin N-linked oligosaccharides in signal transduction. J Biol Chem (1989) 1.05
Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci U S A (1990) 0.98
Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol (2000) 0.98
A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res (1998) 0.95
Parathyroid hormone as a smooth muscle relaxant. Endocr Rev (1989) 0.93
The binding of [3H]oestradiol-receptor complexes to calf uterine chromatin. Biochem J (1981) 0.93
Regulation of inositol 1,4,5-trisphosphate-induced Ca2+ release. I. Effect of Mg2+. Am J Physiol (1990) 0.93
Modification of inflammatory response to implanted biomedical materials in vivo by surface bound superoxide dismutase mimics. J Biomed Mater Res (2000) 0.88
Selectins as potential targets of therapeutic intervention in inflammatory diseases. Biochim Biophys Acta (1994) 0.87
Intratracheal administration of endotoxin and cytokines: VIII. LPS induces E-selectin expression; anti-E-selectin and soluble E-selectin inhibit acute inflammation. Inflammation (1994) 0.86
Alphav and beta1 integrins regulate dynamic compression-induced proteoglycan synthesis in 3D gel culture by distinct complementary pathways. Osteoarthritis Cartilage (2009) 0.86
Synthetic alphaVbeta3 antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication. Endocrinology (1999) 0.86
An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis. Inflamm Res (2008) 0.85
Renal adenylate cyclase and the interrelationship between parathyroid hormone and vitamin D in the regulation of urinary phosphate and adenosine cyclic 3',5'-monophosphate excretion. J Clin Invest (1976) 0.85
Endothelial regulation of cyclic GMP and vascular responses in hypertension. J Pharmacol Exp Ther (1988) 0.85
Multivalent sialyl-LeX: potent inhibitors of E-selectin-mediated cell adhesion; reagent for staining activated endothelial cells. Glycobiology (1994) 0.84
Regional and systemic hemodynamic effects of parathyroid hormone-related protein: preservation of cardiac function and coronary and renal flow with reduced blood pressure. J Pharmacol Exp Ther (1991) 0.84
Insulin enhances pressor responses to norepinephrine in rat mesenteric vasculature. Hypertension (1992) 0.83
Effect of phytate:zinc molar ratio and isolated soybean protein on zinc bioavailability. J Nutr (1981) 0.83
Purinergic vasoconstrictor component revealed by moderate cooling in the isolated mesenteric vasculature of Sprague-Dawley rats. J Pharmacol Exp Ther (1992) 0.83
Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology (1991) 0.83
Deferoxamine as a chelating agent. Clin Toxicol (1971) 0.82
Manganese potentiation of nitric oxide-mediated vascular relaxation. Eur J Pharmacol (1994) 0.82
Endothelium-independent linkage of parathyroid hormone receptors of rat vascular tissue with increased adenosine 3',5'-monophosphate and relaxation of vascular smooth muscle. Endocrinology (1986) 0.82
Cardiovascular responsiveness to parathyroid hormone (PTH) and PTH-related protein in genetic hypertension. Endocrinology (1992) 0.82
Studies on selectin-carbohydrate interactions. Adv Exp Med Biol (1995) 0.82
Bone cell function, regulation, and communication: a role for nitric oxide. J Cell Biochem (1995) 0.81
Induction of refractoriness to isoproterenol by prior treatment of C6-2B rat astrocytoma cells with cholera toxin. J Cyclic Nucleotide Res (1979) 0.81
Increased cyclic AMP in cultured vascular smooth muscle cells and relaxation of aortic strips by parathyroid hormone. Eur J Pharmacol (1985) 0.81
In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. Endocrinology (1990) 0.80
Parathyroid hormone-mediated refractoriness of rat kidney cyclic AMP system. Am J Physiol (1979) 0.80
Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat. Br J Pharmacol (1992) 0.80
Nitric oxide and the cyclooxygenase pathway. Adv Prostaglandin Thromboxane Leukot Res (1995) 0.79
Regulation of skeletal muscle 6-phosphofructo-1-kinase during aging and development. Mech Ageing Dev (1986) 0.78
Role of extracellular magnesium in insulin secretion from rat insulinoma cells. Proc Soc Exp Biol Med (1992) 0.78
Interaction of the radiolabelled high-affinity anti-oestrogen [3H]H1285 with the cytoplasmic oestrogen receptor. Biochem J (1984) 0.78
Analogue separates biological effects of salmon calcitonin on brain and renal cortical membranes. Eur J Pharmacol (1988) 0.78
Temperature sensitivity of cyclic AMP production and catecholamine-induced refractoriness in a rat astrocytoma cell line. Proc Natl Acad Sci U S A (1978) 0.78
Vasodilation of the rat mesenteric vasculature by parathyroid hormone. J Pharmacol Exp Ther (1986) 0.78
Potentiation of cholera toxin-stimulated cyclic AMP production in cultured cells by inhibitors of RNA and protein synthesis. J Biol Chem (1980) 0.78
Radioiodinated rat parathyroid hormone-(1-34) binds to its receptor on rat osteosarcoma cells in a manner consistent with two classes of binding sites. J Bone Miner Res (1990) 0.77
Parathyroid hormone-induced changes in cyclic nucleotide levels during relaxation of the rabbit [correction of rat] aorta. Life Sci (1987) 0.77
Renal prostaglandin efflux induced by vasopressin, dDAVP and arachidonic acid: contrasting profile and sites of release. Clin Exp Pharmacol Physiol (1986) 0.77
Potentiation of nitric oxide-mediated vascular relaxation by SC52608, a superoxide dismutase mimic. Proc Soc Exp Biol Med (1995) 0.77
Effect of dietary calcium supplementation on blood pressure and calciotropic hormones in mineralocorticoid-salt hypertension. J Hypertens (1990) 0.76
Compartmental prostaglandin release by angiotensin II and arginine-vasopressin in rabbit isolated perfused kidneys. Eur J Pharmacol (1986) 0.76
Characterization of the isolated rat mesenteric vascular-intestinal loop preparation. J Pharmacol Toxicol Methods (1992) 0.76
Altered endothelial modulation of vascular tone in aging and hypertension. Blood Vessels (1987) 0.75
Actions of parathyroid hormone in the cardiovascular system. Blood Vessels (1987) 0.75
Hypotension induced by intravascular administration of nerve growth factor in the rat. Clin Sci (Lond) (1991) 0.75
Exaggerated renal thromboxane and prostaglandin release by angiotensin II in suprarenal aortic coarctation hypertension. Pharmacol Res (1989) 0.75
Regulation of renal adenylate cyclase by parathyroid hormone. Am J Physiol (1980) 0.75
Reassessment of noradrenergic function in salt-induced hypertension in Dahl rats. Jpn J Pharmacol (1992) 0.75
Opacities and thioridazine. Am J Psychiatry (1983) 0.75
Interaction of the antiestrogen [3H]H1285 with the two forms of the molybdate-stabilized calf uterine estrogen receptor. J Steroid Biochem (1984) 0.75
Bioavailability of copper in isolated soybean protein using the rat as an experimental model. J Nutr (1984) 0.75
Regulation of the receptor-mediated cyclic AMP response of kidney to parathyroid hormone in the vitamin D-deficient rat. J Supramol Struct (1978) 0.75
Glandular kallikrein levels in the rat anterior pituitary during the estrous cycle and pregnancy. Biol Reprod (1987) 0.75
Infective endocarditis and the dental practitioner. J Okla Dent Assoc (1990) 0.75
One method for the systematic evaluation of adverse drug experience data within a pharmaceutical firm. Methods Inf Med (1977) 0.75